Our Pricing

Mounjaro In Stock UK - All Doses Available Now

Published on: June 03, 2026

Searching for Mounjaro in stock UK all doses? Cured Pharmacy currently holds full availability across all Mounjaro dose strengths, from starter 2.5mg pens through to maintenance 15mg doses. Our UK-registered clinical team can assess your suitability and arrange discreet delivery, typically within 24 hours of prescriber approval.

Current Mounjaro Stock Status at Cured Pharmacy

As of today, Cured Pharmacy maintains confirmed stock of all Mounjaro (tirzepatide) KwikPen doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Unlike the widespread shortages affecting many UK pharmacies throughout 2024, our direct supply agreements with licensed wholesalers ensure consistent availability for patients requiring ongoing treatment.

Each Mounjaro pen is UK-licensed, MHRA-approved, and dispensed only after clinical assessment by our registered prescribers. Pricing starts from £124.99, with transparent costs displayed before you begin your free online consultation — no hidden fees or surprise charges at checkout.

Stock levels are monitored in real-time, and our pharmacy team proactively manages reordering to prevent treatment interruptions. If you've experienced delays or cancellations elsewhere, our superintendent pharmacist Tarun Kumar (GPhC 2233073) has implemented systems specifically designed to maintain continuity of care for weight management patients.

How Mounjaro Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK [1]. This dual-action mechanism sets it apart from single-pathway treatments: tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, gastric emptying, and insulin sensitivity.

In the landmark SURPASS-3 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks — substantially higher than comparator treatments [1]. The SURMOUNT-1 trial, which focused specifically on weight management rather than diabetes control, demonstrated that 91% of participants achieved at least 5% weight loss, with 57% reaching 20% or greater reduction [2].

Clinical effects typically emerge within the first four weeks of treatment. Patients commonly report reduced hunger, earlier satiety during meals, and decreased food cravings. These effects are mediated by the medication's action on appetite-regulating centres in the hypothalamus, not through stimulant mechanisms or metabolic acceleration.

Dosing Schedule and Titration

Treatment begins with a 2.5mg weekly injection for four weeks, allowing your body to adjust to the medication and minimising gastrointestinal side effects. Your prescriber will then increase the dose in 2.5mg increments every four weeks, typically progressing through 5mg, 7.5mg, 10mg, and 12.5mg before reaching the maximum 15mg maintenance dose.

This gradual titration schedule, recommended by the MHRA and supported by clinical trial protocols, significantly reduces the incidence of nausea and vomiting compared to rapid dose escalation [3]. Your UK prescriber may adjust this schedule based on your individual response and tolerability.

Mounjaro vs Wegovy: Understanding Your Options

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are injectable medications licensed in the UK for weight management, but they differ in mechanism, efficacy data, and dosing. Wegovy activates only GLP-1 receptors, whilst Mounjaro's dual GIP/GLP-1 action produces different metabolic effects.

Head-to-head comparison data from the SURPASS-2 trial showed tirzepatide produced superior weight loss compared to semaglutide 1mg (used for diabetes management), with the 15mg tirzepatide dose achieving 5.5kg greater reduction on average [4]. Whilst direct comparison with Wegovy's 2.4mg dose hasn't been published in controlled trials, indirect comparisons suggest tirzepatide may offer enhanced efficacy for some patients.

Wegovy's advantage lies in its earlier market entry and slightly lower starting price point. Some patients also report better gastrointestinal tolerability with semaglutide, though individual responses vary considerably. Your prescriber will consider your medical history, previous treatment responses, and clinical goals when recommending between these options.

Alternative Weight Loss Treatments Available

Beyond injectable GLP-1 medications, Cured Pharmacy offers several evidence-based alternatives. Saxenda (liraglutide) requires daily rather than weekly injection but has extensive safety data from over a decade of clinical use. For patients preferring oral medication, Wegovy oral tablets provide semaglutide in pill form, though absorption requires specific timing around meals.

Orlistat-based treatments (including branded Xenical and Alli) work through a completely different mechanism — blocking dietary fat absorption rather than affecting appetite hormones. These may suit patients with contraindications to GLP-1 medications or those preferring non-injection options, though average weight loss is typically more modest.

Pricing and How to Order Mounjaro

Mounjaro pricing at Cured Pharmacy starts from £124.99 per four-week supply, with the exact cost determined by your prescribed dose strength. We display transparent pricing before you begin your consultation — no registration required to view costs, and no surprise fees during checkout.

The ordering process begins with a free online consultation taking under three minutes to complete. You'll answer questions about your medical history, current medications, weight management goals, and any previous experience with GLP-1 treatments. A UK-registered prescriber reviews your assessment, typically within hours during working days, and either approves your prescription or requests additional information.

Once approved, our pharmacy team dispenses your medication in discreet packaging with no external markings indicating contents. Most orders are dispatched the same working day for next-day delivery via tracked courier. You'll receive injection technique guidance, storage instructions, and direct access to our pharmacist team for any questions during your treatment.

Prescription Requirements and Eligibility

Mounjaro is a prescription-only medication in the UK, meaning it cannot legally be supplied without clinical assessment by a registered prescriber. NICE guidance recommends GLP-1 receptor agonists for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related health conditions such as type 2 diabetes, hypertension, or obstructive sleep apnoea.

Your prescriber will also screen for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or pregnancy. Previous pancreatitis, gallbladder disease, and certain mental health conditions require careful assessment before treatment initiation.

Managing Side Effects and Treatment Expectations

Gastrointestinal side effects — particularly nausea, diarrhoea, constipation, and abdominal discomfort — are the most commonly reported reactions to Mounjaro, affecting up to 30% of patients during dose escalation [1]. These effects typically diminish within 4-8 weeks as your body adjusts, and the gradual titration schedule significantly reduces their severity.

Practical strategies can minimise these effects: eating smaller, more frequent meals rather than large portions; avoiding high-fat and heavily spiced foods during the first weeks; staying well-hydrated; and timing your injection for evenings if nausea tends to peak several hours post-dose. Your pharmacist can provide personalised advice based on your specific symptoms.

More serious but rare side effects include pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, and hypoglycaemia if combined with certain diabetes medications. Seek immediate medical attention if you experience severe persistent abdominal pain, jaundice, or signs of an allergic reaction. Regular monitoring appointments with your prescriber ensure any concerns are identified and managed promptly.

Long-Term Weight Management and Treatment Duration

Clinical trials assessed Mounjaro for up to 72 weeks, demonstrating sustained weight loss throughout this period without plateau effects seen with some older treatments [2]. Real-world evidence suggests many patients maintain treatment for 12-24 months or longer, particularly when combined with lifestyle modifications including dietary changes and increased physical activity.

Weight regain after discontinuation is common, with studies showing patients typically regain approximately two-thirds of lost weight within one year of stopping GLP-1 medications [5]. This reflects the underlying biology of obesity as a chronic condition requiring ongoing management, not a short-term intervention. Your prescriber will discuss realistic expectations and long-term treatment plans during your consultation.

The decision to continue or discontinue treatment should be made collaboratively with your healthcare team, considering factors including weight loss achieved, improvement in weight-related health conditions, side effect tolerability, and personal treatment goals. Some patients transition to maintenance doses or alternative medications, whilst others incorporate planned treatment breaks with close monitoring.

Combining Medication with Lifestyle Changes

Mounjaro is most effective when used as part of a comprehensive weight management programme including dietary modification and increased physical activity. The medication facilitates these changes by reducing hunger and food preoccupation, making it easier to adhere to reduced-calorie eating patterns and establish new habits.

NHS guidance recommends aiming for a 500-600 calorie daily deficit through a combination of reduced intake and increased activity. Your prescriber may suggest referral to specialist weight management services, registered dietitians, or structured programmes that provide additional support alongside medication treatment.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Garvey, W. T., et al. (2022). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X [accessed 13 August 2026]
3. Dahl, D., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Mounjaro is a prescription-only medication that may not be suitable for everyone. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment and lifestyle modifications.